Alzheimer's disease: Translating neurochemical insights into clinical benefits

Journal of Clinical Psychiatry

Volumn 61, Issue 10, 2000, Pages 791-802

  Geula, C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; GALANTAMINE; OLANZAPINE; RISPERIDONE; RIVASTIGMINE; TACRINE;

AGE; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CHOLINERGIC NERVE; CLINICAL TRIAL; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE COURSE; GLIA CELL; HUMAN; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NURSING HOME; PRIORITY JOURNAL; REVIEW;

EID: 0033753796     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n1012     Document Type: Review

References (59)

1. Medical progress: Alzheimer's disease
2. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease
3. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease
4. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
5. Cholinergic markers in elderly patients with early signs of Alzheimer disease
6. Cholinergic dysfunction in diseases with Lewy bodies
7. Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability
8. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
9. Butyrylcholinesterase in the life cycle of amyloid plaques
10. Butyrylcholin-esterase reactivity differentiates the amyloid plaques of aging from those of dementia
11. The spectrum of behavioral changes in Alzheimer's disease
12. Incontinence and troublesome behaviors predict institutionalization in dementia
13. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
14. Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer's disease
15. Anxiety and depressive disorders in adult children caring for demented parents
16. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The neuropsychiatric inventory caregiver distress scale
17. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
18. Olanzapine treatment of psychotic behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
19. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
20. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
21. An economic evaluation of donepezil in the treatment of Alzheimer's disease
22. The effects of rivastigmine on behavioral symptoms in patients in a nursing home setting
23. Mild cognitive impairment: Clinical characterization and outcome
24. Mini-mental state: A practical method for grading the cognitive state of patients for the clinicians
25. The association between quantitative measures of dementia and of senile Change in the cerebral grey matter of elderly subjects
26. The Clinical Dementia Rating (CDR): Current version and scoring rules
27. A prospective study of cognitive function and onset of dementia in cognitively healthy elders
28. Very mild Alzheimer's disease: Informant-based clinical, psychometric, and pathologic distinction from normal aging
29. Attenuation in the progression of cognitive deterioration in Alzheimer's disease with rivastigmine: A dose-dependent effect
30. Is Alzheimer's disease inevitable with age?
31. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease
32. Apolipoprotein E genotype and gender influence response to tacrine
33. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
34. Metrifonate treatment of Alzheimer's disease: Influence of APOE genotype
35. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures
36. Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia
37. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
38. Perspectives in the management of Alzheimer's disease: Clinical profile of donepezil
39. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration
40. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
41. Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease
42. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: A volumetric MRI study
43. Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias
44. Is hippocampal atrophy a specific change for Alzheimer's disease?
45. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
46. Cholinergic deficiency in Alzheimer's disease: Pathogenic model
47. Unbiased whole brain analysis of grey matter loss in Alzheimer's disease
48. Correlation between rates of brain atrophy and cognitive decline in AD
49. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease
50. FMRI of visual encoding: Reproducibility of activation
51. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
52. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
53. Spectrum of ADL impairment and response to rivastigmine varies by severity of Alzheimer's disease
54. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
55. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease